Pharmaceutical Executive March 8, 2024
Davy James

FDA approves Wegovy (semaglutide) to lower the risk of major adverse cardiovascular events in adults with known heart disease and with either obesity or overweight, in addition to a reduced calorie diet and increased physical activity.

The FDA has expanded the indication of Novo Nordisk’s Wegovy (semaglutide) for lowering the risk of major adverse cardiovascular events (MACE) in adults with known heart disease and with either obesity or overweight, in addition to a reduced calorie diet and increased physical activity.1

Wegovy, a glucagon-like peptide-1 (GLP-1) receptor agonist, was initially approved in June 2021 for chronic weight management in those with obesity or overweight and at least one weight-related condition, including high blood pressure, type 2 diabetes, or high cholesterol, in...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma / Biotech
Related Articles:
Insurer Denies Access To Drugs Granted Accelerated Approval By FDA
FDA Approves Third Tocilizumab Biosimilar
The Biden Administration’s Swan Song on Digital Health: Two FDA Guidances on Artificial Intelligence and FDA’s Defense of its Clinical Decision Support Guidance
FDA warns GLP-1 compounder over safety rules
GLP-1 drug approvals: A breakdown

Share This Article